Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

The Competition Commission of India (CCI) recently imposed a penalty of ₹40 lakh on Goldman Sachs (India) Alternative ...

Biocon Biologics CEO discusses revenue growth, market diversification, debt strategy, and impact of US pro-localisation policy.

Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2 ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...

Bengaluru: Biocon Limited, a global biopharmaceuticals company, has announced its Environmental, Social and Governance (ESG) ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

Biocon announced its Environmental, Social and Governance (ESG) scores as assessed by S&P Global's Corporate Sustainability Assessment (CSA) for 2024. Biocon achieved a notable improvement with an S&P ...

Biocon Ltd.'s disappointing Q3FY25 performance was largely due to exceptional items, with adjusted net profit standing at Rs 13 crore, and revenue growth of 7% on a like-for-like basis.